23. Emir Şilit CÇB, Hakan Mutlu, Zekai Pekkafalı, Eşref Kızılkaya, A. Fevzi Karslı. Kemik metastazı taramasında Tc-99m-MDP kemik sintigrafisi ile MRGnin karşılaştırılması. TanIsal ve Girişimsel Radyoloji. 2003;9:357-61. 24. Fleisch H. Bisphosphonates: mechanisms of action. Expert Opin Ther Pat. 2001;11(9):1371-81. 25. Fox A, Patel S, McNair K, Kesingland A, Urban L, Green JR. Zoledronic acid, a potent new bisphosphonate, reverses mechanical hyperalgesia in two rat models of chronic inflammatory and neuropathic pain. Bone. 2001;28(5):S224-S. 26. Füsun Aydoğan RÖ. Kemik sintigrafisinin klinik kullanımı. Tıp Araştırmaları Dergisi. 2010;8(3):210-20. 27. Gennaro A, editor. Remington : The Science and Practice of Pharmacy: Lippincott Williams-Wilkins; 2000. 28. Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies. Semin Oncol. 2001;28(2):4-10. 29. Green JR. Zoledronic acid: pharmacologic profile of a potent bisphosphonate. J Organomet Chem. 2005;690(10):2439-48. 30. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption. Drug Develop Res. 2002;55(4):210-24. 31. Guise TA. Antitumor effects of bisphosphonates: Promising preclinical evidence. Cancer Treat Rev. 2008;34:S19-S24. 32. Hammermaier A, Reich E, Bogl W. Chemical, radiochemical, and radionuclide purity of eluates from different commercial fission Mo-99 Tc-99m generators. Eur J Nucl Med. 1986;12(1):41-6. 33. Handeland AM, Sundrehagen E. Determination of the oxidation state of 99mTc in complexes with MDP and DTPA. Int J Rad Appl Instrum A. 1987;38(6):479-84. 34. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 2000;18(6):1378-91. 35. Hirabayashi H, Fujisaki J. Bone-specific drug delivery systems – Approaches via chemical modification of bone-seeking agents. Clin Pharmacokinet. 2003;42(15):1319-30. 36. Holder LE. Bone-scintigraphy in skeletal trauma. Radiol Clin N Am. 1993;31(4):739-81. 37. http://en.wikipedia.org/wiki/Zoledronic_acid 38. http://genelbiyoloji.com/wp-content/uploads/2010/05/histoloji_5.pdf. 39. http://www-pub.iaea.org/MTCD/publications/PDF/Pub1405_web.pdf. Technetium99m Radiopharmaceuticals : Status and Trends. Vienna: International Atomic Energy Agency; 2009. 40. http://www.iaea.org. 41. http://www.zometa.com. 42. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in-vitro and in-vivo. J Bone Miner Res. 1995;10(10):1478-87. 43. Hughes S. The distribution of 99mTc-EHDP in the tissues of the dog and its application in the assessment of fracture healing. Ann R Coll Surg Engl. 1977;59(4):322-7. 44. İlem D. Alendronat Sodyumun Farklı Formülasyonlardaki Biyoyararlanımı [Yüksek Lisans Tezi]. İzmir: Ege Üniversitesi, Sağlık Bilimleri Enstitüsü; 2008. 45. Imran MB, Khurshid SJ, Karim HMA. Biological and radiochemical quality-control of indigenous Tc(99m)-radiopharmaceutical kits. J Radioan Nucl Ch Le. 1993;176(3):21123. 46. Khalil MM, (Ed). Basic Sciences of Nuclear Medicine. Berlin: Springer; 2007. 47. Koji Nakanishi PHS,(Ed). Infrared Absorption Spectroscopy. 2nd Edition ed. San Francisco: Holden-Day Inc; 1977. 48. Kowalsky RJ, editor. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine. Second Edition ed: Ame rican Pharmacists Association; 2004.
141



154. SAYFAYA BENZER SAYFALAR

tabs_sener_yagiz_191898 - Sayfa
...


154. SAYFA ICERIGI

23. Emir Şilit CÇB, Hakan Mutlu, Zekai Pekkafalı, Eşref Kızılkaya, A. Fevzi Karslı. Kemik metastazı taramasında Tc-99m-MDP kemik sintigrafisi ile MRGnin karşılaştırılması. TanIsal ve Girişimsel Radyoloji. 2003;9:357-61. 24. Fleisch H. Bisphosphonates: mechanisms of action. Expert Opin Ther Pat. 2001;11(9):1371-81. 25. Fox A, Patel S, McNair K, Kesingland A, Urban L, Green JR. Zoledronic acid, a potent new bisphosphonate, reverses mechanical hyperalgesia in two rat models of chronic inflammatory and neuropathic pain. Bone. 2001;28(5):S224-S. 26. Füsun Aydoğan RÖ. Kemik sintigrafisinin klinik kullanımı. Tıp Araştırmaları Dergisi. 2010;8(3):210-20. 27. Gennaro A, editor. Remington : The Science and Practice of Pharmacy: Lippincott Williams-Wilkins; 2000. 28. Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies. Semin Oncol. 2001;28(2):4-10. 29. Green JR. Zoledronic acid: pharmacologic profile of a potent bisphosphonate. J Organomet Chem. 2005;690(10):2439-48. 30. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption. Drug Develop Res. 2002;55(4):210-24. 31. Guise TA. Antitumor effects of bisphosphonates: Promising preclinical evidence. Cancer Treat Rev. 2008;34:S19-S24. 32. Hammermaier A, Reich E, Bogl W. Chemical, radiochemical, and radionuclide purity of eluates from different commercial fission Mo-99 Tc-99m generators. Eur J Nucl Med. 1986;12(1):41-6. 33. Handeland AM, Sundrehagen E. Determination of the oxidation state of 99mTc in complexes with MDP and DTPA. Int J Rad Appl Instrum A. 1987;38(6):479-84. 34. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 2000;18(6):1378-91. 35. Hirabayashi H, Fujisaki J. Bone-specific drug delivery systems – Approaches via chemical modification of bone-seeking agents. Clin Pharmacokinet. 2003;42(15):1319-30. 36. Holder LE. Bone-scintigraphy in skeletal trauma. Radiol Clin N Am. 1993;31(4):739-81. 37. http://en.wikipedia.org/wiki/Zoledronic_acid 38. http://genelbiyoloji.com/wp-content/uploads/2010/05/histoloji_5.pdf. 39. http://www-pub.iaea.org/MTCD/publications/PDF/Pub1405_web.pdf. Technetium99m Radiopharmaceuticals : Status and Trends. Vienna: International Atomic Energy Agency; 2009. 40. http://www.iaea.org. 41. http://www.zometa.com. 42. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in-vitro and in-vivo. J Bone Miner Res. 1995;10(10):1478-87. 43. Hughes S. The distribution of 99mTc-EHDP in the tissues of the dog and its application in the assessment of fracture healing. Ann R Coll Surg Engl. 1977;59(4):322-7. 44. İlem D. Alendronat Sodyumun Farklı Formülasyonlardaki Biyoyararlanımı [Yüksek Lisans Tezi]. İzmir: Ege Üniversitesi, Sağlık Bilimleri Enstitüsü; 2008. 45. Imran MB, Khurshid SJ, Karim HMA. Biological and radiochemical quality-control of indigenous Tc(99m)-radiopharmaceutical kits. J Radioan Nucl Ch Le. 1993;176(3):21123. 46. Khalil MM, (Ed). Basic Sciences of Nuclear Medicine. Berlin: Springer; 2007. 47. Koji Nakanishi PHS,(Ed). Infrared Absorption Spectroscopy. 2nd Edition ed. San Francisco: Holden-Day Inc; 1977. 48. Kowalsky RJ, editor. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine. Second Edition ed: Ame rican Pharmacists Association; 2004.
141




single.php